جدول الترويج Vincerx Pharma, Inc.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. مزيد من التفاصيل| IPO date | 2020-05-27 |
|---|---|
| ISIN | US92731L1061 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://vincerx.com |
| Цена ао | 0.6026 |
| تغير السعر يوميا: | -4.85% (0.5666) |
|---|---|
| تغير السعر في الأسبوع: | -16.81% (0.648) |
| تغير السعر شهريا: | -50.54% (1.09) |
| تغير السعر خلال 3 أشهر: | -86.11% (3.88) |
| تغير السعر على مدى ستة أشهر: | -96.24% (14.32) |
| تغير السعر سنويا: | -89.35% (5.06) |
| تغير السعر على مدى 3 سنوات: | -87.61% (4.35) |
| تغير الأسعار منذ بداية العام: | -89.75% (5.26) |
|
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
|||||||||||||||||||||||||||||||||||||
| المؤسسات | مقدار | يشارك, % |
|---|---|---|
| Goldman Sachs Group Inc | 1709656 | 7.98 |
| Sage Rhino Capital LLC | 1703413 | 7.95 |
| Long Focus Capital Management, LLC | 1098753 | 5.13 |
| Bank of America Corporation | 1082863 | 5.06 |
| Rock Springs Capital Management, LP | 891719 | 4.16 |
| Vanguard Group Inc | 513420 | 2.4 |
| Kingdon Capital Management LLC | 385000 | 1.8 |
| Rubric Capital Management LP | 354377 | 1.65 |
| Point72 Asset Management, L.P. | 344827 | 1.61 |
| ExodusPoint Capital Management, LP | 324119 | 1.51 |
| مشرف | مسمى وظيفي | قسط | سنة الميلاد |
|---|---|---|---|
| Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman & CEO | 657.54k | 1965 (60 سنين) |
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, COO, Secretary & Director | 591.54k | 1970 (55 سنين) |
| Mr. Alexander A. Seelenberger M.B.A. | Chief Financial Officer | 491.69k | 1979 (46 سنين) |
| Mr. Tom C. Thomas J.D. | Founder, General Counsel & Chief Legal Officer | 444.14k | 1960 (65 سنين) |
| Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board | N/A | |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer | N/A | |
| Ms. Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff | N/A | |
| Ms. Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | N/A | |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer | N/A | |
| Ms. Karen Quarford M.B.A. | Vice President of Quality Operations & Compliance |
عنوان: United States, Palo Alto. CA, 260 Sheridan Avenue - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://vincerx.com
موقع إلكتروني: https://vincerx.com
